CLOVHealthcare · Healthcare PlansThe 5 Wall Street analysts covering Clover Health Investments Corp. hold a median 12-month price target of $5.5 — +17.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Clover Health Investments Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (85): Analysts have, on balance, been raising their forecasts.
Volatility (31): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CLOV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Needham | Initiates | Buy | $6.00 |
| 6 Aug 2026 | UBS | Maintains | Neutral | — |
| 6 Aug 2026 | UBS | Maintains | Neutral | $4.75 → $5.00 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $4.20 → $5.50 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 June 2026 | UBS | Maintains | Neutral | $2.75 → $4.75 |
| 11 June 2026 | UBS | Maintains | Neutral | — |
| 4 June 2026 | Canaccord Genuity | Maintains | Buy | $3.20 → $4.20 |
| 4 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 20 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2026 | Leerink Partners | Maintains | Market Perform | — |
| 20 Jan 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Aug 2025 | UBS | Maintains | Neutral | — |
| 3 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 17 Dec 2024 | Craig-Hallum | Initiates | Buy | — |
| 7 Oct 2024 | UBS | Initiates | Neutral | — |
| 11 Aug 2023 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2023 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLOV appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Clover Health Investments Corp. returned +32.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 70% of US stocks
Cheaper than 15% of US stocks
Cheaper than 97% of US stocks
Higher than 87% of US stocks
Higher than 76% of US stocks
Higher than 22% of US stocks
Higher than 52% of US stocks
Higher than 29% of US stocks
Higher than 39% of US stocks
Higher than 38% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Clover Health Investments Corp. has a market value of $2.3B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter grew 55.6% year on year.
Net income over the same four quarters: −$18.4M, a −0.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.05.
Free cash flow in the twelve months to 30 June 2026: $74.2M.
Clover Health Investments Corp. spent $24.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −25.3×; forward P/E: 28.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Clover Health Investments Corp. employs 724 people — $3.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| CLOVClover Health Investments Corp. | $2.3B | 72 |
| PGNYProgyny, Inc. | $2.4B | 99 |
| ALHCAlignment Healthcare, Inc. | $1.7B | 42 |
| OSCROscar Health, Inc. | $10.5B | 90 |
| MOHMolina Healthcare, Inc. | $11.8B | 34 |
| CNCCentene Corp. | $37.4B | 93 |
| NAMSNewAmsterdam Pharma Co. NV* | $2.4B | 57 |
* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Clover Health Investments Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Clover Health reported a third-quarter profit, raised the lower end of its 2026 financial guidance, and said it expects its first full year of GAAP net income profitability.
Why it matters — The update gives CLOV watchers information about the company’s reported quarterly results and its stated profitability outlook.
Clover Health reported third-quarter 2026 revenue of $759 million, up 53% year over year, and GAAP net income of $6 million. It also raised its full-year 2026 guidance across membership, revenue, net income, gross profit and adjusted EBITDA.
Why it matters — The results and higher guidance provide CLOV watchers updated information on membership growth, financial performance and the company’s outlook.
Clover Health announced that Interim Chief Financial Officer Clay Thornton will present at the 2026 UBS Global Healthcare Conference on November 9, 2026, at 12:30 p.m.
Why it matters — CLOV watchers may note the scheduled conference appearance by the company’s interim CFO.
Clover Health announced it earned top distinctions in U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage ratings across New Jersey, Georgia, and South Carolina.
Why it matters — The recognition provides CLOV watchers with an update on the company’s Medicare Advantage ratings in three states.
Clover Health announced that CMS awarded its PPO Medicare Advantage plans a 5-star rating and its HMO plan a 4.5-star rating for 2027. The ratings affect payment year 2028.
Why it matters — The CMS ratings provide CLOV watchers information about the company's Medicare Advantage plan ratings and the payment year they affect.
The 5 Wall Street analysts covering Clover Health Investments Corp. have a median 12-month price target of $5.5, with estimates ranging from $5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Clover Health Investments Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clover Health Investments Corp. 72 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Clover Health Investments Corp. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (85 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +17.8% from the last close, and Ticker Nerd's factor model ranks Clover Health Investments Corp. 72 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Clover Health Investments Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $6 over the next 12 months.
Clover Health Investments Corp. returned +32.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Clover Health Investments, Corp. Class A Common Stock represents an equity interest in Clover Health Investments, Corp., a healthcare company focused on Medicare Advantage plans in the United States.
The most recent item we track (MarketBeat, 5 Nov 2026): "What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call". Clover Health reported a third-quarter profit, raised the lower end of its 2026 financial guidance, and said it expects its first full year of GAAP net income profitability.
Clover Health Investments, Corp. Class A Common Stock represents an equity interest in Clover Health Investments, Corp., a healthcare company focused on Medicare Advantage plans in the United States. The company serves Medicare-eligible individuals through preferred provider organization and health maintenance organization plans, with a strong emphasis on broad-network coverage and coordinated care. Clover Health also operates Clover Assistant, a proprietary software platform that supports physicians by aggregating patient data and helping identify and manage chronic conditions earlier. Its business is centered on the insurance segment, combining managed care offerings with technology-enabled clinical support for medical providers. Based in Wilmington, Delaware, Clover Health occupies a niche in the healthcare market where insurance delivery and data-driven care management intersect.
CEO Mr. Andrew Toy · 724 employees · United States · https://www.cloverhealth.com
